86 results about "Carnitine metabolism" patented technology

A topical composition comprising a lipoic acid, a carnitine, and a carnosine in a suitable vehicle for topical application and a method for treating skin is provided. The present compositions are useful in improving the appearance of aged skin characterized by wrinkles and loss of elasticity. Preferred components include R-lipoic acid or R-dihydrolipoic acid, acetyl-1-carnitine, and 1-carnosine.

The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ω-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and subtantially lacking in free amino acids.

A method for mimicking the effects of caloric restriction by administration of a food substrate having carnitine or a carnitine derivative and an antioxidant. The food substrate is capable of modulating gene expression in a way similar to caloric restriction.

Compounds of formula (I)wherein the groups are as defined in the description are disclosed.The compounds of formula (I) are endowed with reversible inhibiting activity of carnitine palmitoyl-transferase and are useful in the preparation of medicaments useful in the pathologies related to a hyperactivity of carnitine palmitoyl-transferase, such as hyperglycemia, diabetes and pathologies related thereto, heart failure, ischemia.

A composition for enhancing cellular energy that includes creatine, L-arginine-α-ketoglutarate, D-ribose, L-carnitine, L-citrulline, and pyruvate. The composition is administering to a subject to enhance cellular energy, to increase relative intensity of physical activity performed by the subject, to increase endurance of the subject during the physical activity and to increase the muscle mass of the subject.

The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ω-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.

The present invention relates to the unexpected discovery that a combination of effective amounts of carnitine (in any form, as described in further detail herein) and conjugated linoleic acid (CLA) administered to a patient in need thereof exhibits synergistic activity in treating obesity by reducing fat mass and overall weight as well as one or more of hyperlipidemia, hypercholesterolemia, diabetes (both diabetes mellitus I and II), metabolic syndrome (syndrome X), kidiney failure and high blood pressure, where those conditions exist.

The present invention is directed to compositions and methods of delivery of CoQ-10 and an amino acid solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to incorporate greater amounts of bioactive CoQ-10 and the amino acid, such as carnitine, i.e., carnitine tartrate, in formulations, such as soft gel capsules.

The present invention is directed to compositions and methods of delivery of CoQ-10 and an amino acid solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to incorporate greater amounts of bioactive CoQ-10 and the amino acid, such as carnitine, i.e., carnitine tartrate, in formulations, such as soft gel capsules.

The present invention relates to a novel method of treating male infertility such as, for example, idiopathic asthenospermia. In one aspect the present invention relates to the treatment or prevention of male infertility through the administration of a composition containing ubiquinone, ubiquinol or both, and optionally, a member chosen from the group consisting of a reducing agent, a solubilizer, an emulsifier, a surfactant, a triglyceride, an oil, a fat, a lipid, a phospholipid, a carbohydrate, an antioxidant, a carnitine, creatine, an herbal extract, a vitamin, a coenzyme, a mineral, an electrolyte, a pharmaceutical, a water, a carrier, an excipient, and any combination thereof.

Compositions useful for weight management in an animal are disclosed. The compositions comprise one or more isoflavones or isoflavone metabolites, and in some embodiments include conjugated linoleic acid, and / or L-carnitine. Also disclosed are methods useful for weight management in an animal utilizing compositions comprising one or more isoflavones, conjugated linoleic acid, and / or L-carnitine. Preferably, the compositions and methods employ a combination of one or more isoflavones, or a combination of one or more isoflavones in conjunction with conjugated linoleic acid, and L-carnitine.

A hearing health micronutrient formulation is provided and the formulation comprises dietary antioxidants and endogenous antioxidants, and the dietary antioxidants are selected from a group consisting essentially of Vitamin A (Palmitate), Vitamin E, Vitamin C (Calcium Ascorbate), Vitamin D3 (Cholecalciferol), B Vitamins, Biotin, Pantothenic Acid (as D-Calcium Pantothenate), Calcium Citrate, Magnesium Citrate, Zinc Glycinate, Selenium (Seleno-L-Methionine), Chromium (as Chromium Picolinate), Mixed Carotenoids and mixtures thereof, and the endogenous antioxidants are selected from a group consisting essentially of N-Acetyl Cysteine (NAC), Coenzyme Q10, R-alpha Lipoic Acid, L-Carnitine and mixtures thereof,

The present invention discloses novel dual prodrug compositions of Formula 1, wherein A is a single bond, —O—, or —CH2—; m and n vary from 0 to 15; p and q vary from 0 to 4; B is a single bond or —CR3R4; D is selected from the group consisting —CO2R5, —OR6, —OCOR7, —SO3R8, —SO2NH2, —OPO(OR9)(OR10), —OPO(OR9)(NH2), —OPO(OR9)—O—PO(OR10)(OR11), R1 to R11 are various substituents selected to optimize the physicochemical and biological properties such as, lipophilicity, toxicity, bioavailability, and pharmacokinetics of compounds of Formula 1. These compounds are useful for the treatment of various cardiovascular and neurological disorders.

The invention discloses monohydroxy conjugated linoleic acid, a preparation method and application thereof, which relate to a novel conjugated linoleic acid derivative, namely the monohydroxy conjugated linoleic acid, the preparation method and the application thereof. The compounds are the monohydroxy conjugated linoleic acid obtained by following steps: stirring linoleic acid and selenium dioxide for 0.5 to 2h at a temperature of between 25 and 60 DEG C; continuing stirring to react for 12 to 48 hour; and adding water to wash the obtained product; collecting an organic solvent layer and recovering a solvent, wherein a molecular formula is C18H32O3, and the morphology is yellowish oily matter. The monohydroxy conjugated linoleic acid is used for preparing medicaments or food for treating obesity or reducing blood fat or reducing blood sugar or improving the immunity or resisting tumor, and preparing antioxidative and whitening skin nursing preparations for external application. L-carnitine can also be added into dihydroxyoleic acid to prepare medicaments or food for treating obesity or reducing blood fat or reducing blood sugar or serve as a feed additive, and the weight ratio ofthe monohydroxy conjugated linoleic acid to the L-carnitine in a product is 4:1-8.

An object of the present invention is to provide skin external preparations and cosmetics which contain a branched acyl carnitine and have excellent formulation stability. A skin external preparation of the present invention includes a carnitine derivative represented by the following Formula (1) and / or a carnitine derivative salt represented by the following Formula (2), and an amphoteric surfactant.In Formula (1), R1 and R2 are each independently a C1-18 optionally branched, saturated or unsaturated aliphatic hydrocarbon group. In Formula (2), R1 and R2 are the same as in Formula (1), X− is a specific anion and Y+ is a specific cation.

Pharmaceutical products for nasal administration contain peptide active agents and are formulated with compounds that enhance bioavailability of the peptide active agents. In particular, citrates, fatty acids, sugar esters of fatty acids or acyl carnitines are used. In some embodiments, a sugar ester of a fatty acid is used in combination with either a fatty acid, or alternatively, an acyl carnitine.

The present invention relates to a composition for slimming, more particularly, to a slimming composition containing theanine and at least on selected from the group consisting of caffeine, genistein, L-carnitine and catechin. The composition of the present invention contains theanine and each of caffeine, genistein, L-carnitine or mixtures thereof, and has properties of decomposing fats, hydrolyzing lipid and removing cellulites.

The present invention relates to a composition containing genistein that accelerates the expression of the Carnitine Palmitoyl Transferase-1 (CPT-1) for improving or treating obesity. More particularly, the composition of the present invention comprises genistein that accelerates the expression of the CPT-1, an important enzyme for the lipolysis of fatty acid, and comprises carnitine that transports fatty acid into mitochondria and accelerates oxidation of fat in the oxidation process of fatty acid.

There is a topical composition having carnitine creatinate and a cosmetically acceptable vehicle. There is also provided a method for improving the aesthetic appearance of skin. There is also provided a method for inhibiting the induced lipid synthesis in skin. There is also provided a method for inhibiting the formation of cellulite in skin.

A process for the preparation and separation of the pentoses, xylose and arabinose from mixtures of saccharides by forming acetals is described. D-xylose is a precursor to xylitol, a sweetener, and L-arabinose is a precursor to the drug intermediate (R)-3,4-dihydroxybutyric acid, carnitine and agrichemicals.

In a new pharmaceutical combination, the herb, Vitex agnus-castus (chasteberry), enhances hormone balance by increasing progesterone release and, therefore, ovulation frequency. The antioxidants, green tea, vitamin E, and selenium, improve overall reproductive health. L-arginine, an amino acid, stimulates the reproductive organs by improving circulation. Folic acid, vitamins B6 and B12, iron, zinc and magnesium help promote womens' fertility. Sperms are highly susceptible to free radical or oxidative damage from environmental toxicants and natural aging. Vitamins C and E, coenzyme Q10 and selenium are all potent antioxidants that help improve sperm counts and quality. Ferulic acid, an antioxidant found in Dong quai, also improves sperm quality. Zinc and B vitamins (B6, B12 and folate) are critical nutrients in male reproductive systems for hormone metabolism, sperm formation and motility. The amino acid, L-carnitine, promotes formation of healthy sperm.

Improved compositions and methods are useful in the treatment and prevention of impulsive, compulsive, reward-seeking, and other addictive behaviors, including applications involving the behavioral / cognitive process of assigning importance, maintaining attention, and assessing salience. The composition includes Vitex agnus-castus (Chastetree berry) extract in an effective amount for supporting and promoting a healthy lifestyle free from addictive behavior or for preventing or treating addictive behavior. The composition also includes garcinia cambogia, aspartic acid, pyruvate, EPA (eicosapentanoic acid), biotin, L-carnitine, and chromium polynicotinate.

A nutritional composition for the treatment of syndromes related to dysfunctional energy metabolism is provided. The composition comprises a combination of L-carnitine, acetyl-L-carnitine, pantothenate and niacinamide. Methods of treatment of dysfunctional energy metabolism are also disclosed.

Pharmaceutical compositions and methods of preventing or reducing hearing or balance loss and damage to ear cells in patients who have been exposed to toxic levels of noise and other toxic insults are provided. These methods comprise administering an effective amount of a protectant combination or composition comprising two or more protectants selected from the group of methionine protectant agents, N-acetylcysteine, carnitine, magnesium ions, lipoic acid, ebselen, glutathione, and glutathione ester. These protectant combinations can be administered prior to, simultaneously with, or subsequently to exposure to noise other toxic insults.

A micronutrient formulation system is provided and the system comprises: a first composition comprising alpha tocopherol and derivative esters of alpha tocopherol, the derivative esters of alpha tocopherol being selected from a group consisting essentially of alpha tocopheryl acetate, alpha tocopheryl palmitate, alpha tocopheryl succinate, alpha tocopheryl nicotinate and mixtures thereof; a second composition comprising vitamin A and natural-mixed carotenoids; a third composition comprising calcium ascorbate; a fourth composition selected from a group consisting essentially of B-vitamins, selenium, zinc, magnesium, chromium and mixtures thereof; and a fifth composition selected from a group consisting essentially of alpha lipoic acid, co-enzyme Q10, L-carnitine, n-acetyl cysteine and mixtures thereof, wherein said formulation is without iron, copper and manganese.

Use of L-carnitine and / or of one or more alkanoyl L-carnitines or one of their pharmaceutically acceptable salts for the preparation of an opthalmic physiological supplement or medicament in the form of eye-drops, for the treatment of corneal diseases.

The present invention provides a method of improving the visual acuity of a person in need thereof which comprises topically administering to said person, in an effective amount, an ophthalmic composition comprising an aqueous carrier component; and an effective amount of a tonicity component comprising a material selected from a combination of compatible solute agents, wherein said combination of compatible solute agents comprises two polyol components and one amino acid component and wherein said polyol components are erythritol and glycerol and said amino acid component is carnitine.

A provided preparation method for high-optical-purity L-carnitine comprises the steps: step 1) taking ethyl 4-chloroacetoacetate as the raw material, performing a hydroboration reduction reaction to obtain ethyl 4-chloro-3-hydroxybutyrate; step 2) taking ethyl 4-chloro-3-hydroxybutyrate obtained in the step 1) as the reaction initiator, under the catalytic effect of immobilized lipase, performing an asymmetric esterification reaction with an acyl donor to obtain an ethyl (R)-4-chloro-3-hydroxybutyrate esterified compound and ethyl (S)-4-Chloro-3-Hydroxybutyrate; and step 3) taking the ethyl (R)-4-chloro-3-hydroxybutyrate esterified compound as the reaction initiator, performing condensation with trimethylamine, then performing a hydrolysis reaction to obtain L-carnitine. The preparation method provided by the invention has the advantages of easily available reaction raw materials, high product yield, high optical purity and reusable by-products, and is applicable to industrialized production.